This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Second Reply to Letter to the Editor re: “Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting”
Prostate Cancer and Prostatic Diseases Open Access 28 August 2019
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carroll PR, Parsons JK, Andriole G, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): prostate cancer early detection, version 2. 2017. www.nccn.org.
Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5.
Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464–70.
White J, Shenoy BV, Tutrone RF, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer Prostatic Dis. 2018;21:78–84.
Funding
This work was supported in part by funds from the Sidney Kimmel Center for Prostate and Urologic Cancers, a Specialized Programs of Research Excellence grant (P50-CA92629) from the National Cancer Institute to Dr. Howard Scher, and a National Institutes of Health/National Cancer Institute Cancer Center Support Grant (P30-CA008748) to Memorial Sloan Kettering Cancer Center, a grant from the National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network (U01CA199338-02), and the David H. Koch prostate cancer research fund.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
SC has received a lecture fee and travel support from Astellas unrelated to this letter. The sponsor had no role in the writing of this letter, in the analysis or interpretation of data, and in the decision to publish the letter.
Rights and permissions
About this article
Cite this article
Ehdaie, B., Carlsson, S. Reply to ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’. Prostate Cancer Prostatic Dis 21, 446–447 (2018). https://doi.org/10.1038/s41391-018-0052-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-018-0052-y
This article is cited by
-
Second Reply to Letter to the Editor re: “Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting”
Prostate Cancer and Prostatic Diseases (2019)
-
Reply to Letter to the Editor re: ‘Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting’
Prostate Cancer and Prostatic Diseases (2018)